Program
Amlodipine
Also written as “amlodipine”, “Amlodipine 5 mg” and “Amlodipine 10 mg”.
Its studies are mostly in Hypertension · Essential Hypertension · Hyperlipidemias · Kidney Diseases · Hypercholesterolemia, led by 35 companies.
Drug pageAmlodipine: every studyMany companies study it; this page follows only the 170 they lead. All 284 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 570 open or running | phase 4since Aug 25, 2005 | Aug 25, 2005 | none ahead |
| Boehringer Ingelheimits history only | 220 open or running | phase 4since Oct 14, 2005 | Oct 14, 2005 | none ahead |
| Viatrisits history only | 130 open or running | phase 4since Aug 31, 2005 | Aug 31, 2005 | none ahead |
| Hanmi Pharmaceuticalits history only | 110 open or running | phase 3since Jul 14, 2009 | Jul 14, 2009 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 80 open or running | phase 1since May 26, 2010 | May 26, 2010 | none ahead |
| HK inno.Nits history only | 50 open or running | phase 3since Feb 16, 2015 | Feb 10, 2014 | none ahead |
| Handokits history only | 40 open or running | phase 3since Jul 24, 2022 | Jul 21, 2020 | none ahead |
| Teva Pharmaceutical Industriesits history only | 40 open or running | phase 1since Feb 9, 2009 | Feb 9, 2009 | none ahead |
| Yuhanits history only | 41 open or running | phase 4since Sep 4, 2023 | May 29, 2014 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 30 open or running | phase 3since Jan 8, 2016 | Feb 14, 2014 | none ahead |
| Daewoong Pharmaceuticalits history only | 30 open or running | phase 3since Dec 12, 2016 | Mar 4, 2013 | none ahead |
| IlDong Pharmaceuticalits history only | 30 open or running | phase 3since Apr 11, 2016 | Mar 31, 2016 | none ahead |
| Merckits history only | 30 open or running | phase 3since Feb 22, 2011 | Nov 10, 2008 | none ahead |
| Daewon Pharmaceuticalits history only | 20 open or running | phase 3since Oct 12, 2016 | Oct 12, 2016 | none ahead |
| Hikma Pharmaceuticalsits history only | 20 open or running | no phasesince Jan 15, 2008 | Jan 15, 2008 | none ahead |
| Jeil Pharmaceuticalits history only | 20 open or running | phase 1since Mar 9, 2015 | Mar 9, 2015 | none ahead |
| Menarini Groupits history only | 20 open or running | phase 4since Mar 4, 2022 | Mar 4, 2022 | none ahead |
| Midas Pharmaits history only | 20 open or running | phase 1since Jan 23, 2020 | Jan 23, 2020 | none ahead |
| Sun Pharmaceutical Industriesits history only | 20 open or running | no phasesince Oct 16, 2008 | Oct 16, 2008 | none ahead |
| Torrent Pharmaceuticalsits history only | 20 open or running | phase 1since Jul 1, 2009 | Jul 1, 2009 | none ahead |
| TSH Biopharmits history only | 20 open or running | phase 4since Jun 15, 2011 | Jun 15, 2011 | none ahead |
| Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratoriesits history only | 10 open or running | phase 1since Mar 10, 2016 | Mar 10, 2016 | none ahead |
| Celltrionits history only | 10 open or running | phase 3since Apr 27, 2026 | Apr 27, 2026 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Jul 30, 2015 | Jul 30, 2015 | none ahead |
| Hyundai Pharmits history only | 11 open or running | phase 3since Oct 15, 2024 | Oct 15, 2024 | none ahead |
| InVasc Therapeutics | 10 open or running | phase 4since Jan 5, 2011 | Jan 5, 2011 | none ahead |
| Kitov Pharmaceuticalsits history only | 10 open or running | phase 3since Jun 20, 2014 | Jun 20, 2014 | none ahead |
| Lotus Pharmaceuticalits history only | 10 open or running | phase 1since May 23, 2016 | May 23, 2016 | none ahead |
| Organonits history only | 10 open or running | phase 4since Aug 30, 2005 | Aug 30, 2005 | none ahead |
| Pfizerits history only | 10 open or running | phase 3since Mar 2, 2007 | Mar 2, 2007 | none ahead |
| Servierits history only | 10 open or running | phase 3since Feb 25, 2022 | Feb 25, 2022 | none ahead |
| Shanghai Haini Pharmaceuticalits history only | 10 open or running | phase 1since Nov 17, 2016 | Nov 17, 2016 | none ahead |
| Shin Poong Pharmaceuticalits history only | 10 open or running | phase 2since Oct 24, 2016 | Oct 24, 2016 | none ahead |
| Takedaits history only | 10 open or running | phase 3since Nov 17, 2016 | Nov 17, 2016 | none ahead |
| Zentiva, k.s.its history only | 11 open or running | phase 3since May 25, 2026 | May 25, 2026 | Dec 31, 2027phase 3 · NCT07618806 |
Also a collaborator on its studies: CSPC Pharmaceutical Group and Integrium.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of InVasc Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 5, 2011First study: phase 4 study in HypertensionFirst studyNCT01271374 · 80 enrolled · United States
TargetBeta
“Voltage-gated L-type calcium channel blocker; Voltage-gated L-type calcium channel blocker; Voltage-gated L-type calcium channel blocker”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Pregabalinrule | Viatris | phase 4 | 149 |
| Gabapentinrule | Viatris | phase 4 | 49 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| Nifedipinerule | Bayer | phase 4 | 18 |
Studies
The one study InVasc Therapeutics leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01271374Hypertension · United States | 4 | UNKNOWN | Jun 2011 | 80 |
How it is read
Names in the registry
- “Amlodipine”, 44 entries
- “amlodipine”, 14 entries
- “Amlodipine 5 mg”, 9 entries
- “Amlodipine 10 mg”, 6 entries
- “valsartan + amlodipine”, 5 entries
Conditions, from the studies’ own filings
- Hypertension, 119 studies
- Essential Hypertension, 32 studies
- Hyperlipidemias, 3 studies
- Kidney Diseases, 1 study
- Hypercholesterolemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.